- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: Auer rods.
Displaying page 1 of 1.
EudraCT Number: 2016-004907-30 | Sponsor Protocol Number: AG120-C-009 | Start Date*: 2017-09-13 | |||||||||||
Sponsor Name:Agios Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated Acute Myeloid Leukemia w... | |||||||||||||
Medical condition: Acute Myeloid Leukemia with an IDH1 Mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) AT (Completed) CZ (Completed) NL (Ongoing) FR (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001643-39 | Sponsor Protocol Number: 2215-CL-0302 | Start Date*: 2017-02-09 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. (APGD) | |||||||||||||
Full Title: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy... | |||||||||||||
Medical condition: Subjects diagnosed with FLT3/ITD acute myeloid leukemia (AML) in CR1, including CRp and CRi, for whom a decision not to proceed with transplantation has been made, or a suitable donor could not be ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) CZ (Completed) PL (Completed) PT (Completed) SE (Completed) GR (Completed) DK (Completed) HR (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001253-23 | Sponsor Protocol Number: 4202-ONC-203 | Start Date*: 2022-09-23 |
Sponsor Name:Forma Therapeutics, Inc. | ||
Full Title: A Phase 2 Open-Label Study to Evaluate Etavopivat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS) | ||
Medical condition: Anemia of myelodysplastic syndromes (MDS), inherited hemolytic anemias, and other refractory anemias | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001061-83 | Sponsor Protocol Number: 2215-CL-0304 | Start Date*: 2017-07-13 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. | |||||||||||||
Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with... | |||||||||||||
Medical condition: FMS-like tyrosine kinase 3 (FLT3) / internal tandem duplication (ITD) (FLT3/ITD) acute myeloid leukemia (AML) in first morphologic complete remission (CR1) that has been treated with allogeneic hem... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Temporarily Halted) GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) PL (Completed) DK (Completed) FR (Ongoing) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001290-15 | Sponsor Protocol Number: HO97 | Start Date*: 2009-03-18 | |||||||||||
Sponsor Name:HOVON Foundation | |||||||||||||
Full Title: Randomized maintenance therapy with Azacitidine (Vidaza) in older patients (≥ 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t). A phase ... | |||||||||||||
Medical condition: Acute myeloid leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004134-42 | Sponsor Protocol Number: SLSG18-301 | Start Date*: 2020-09-22 | |||||||||||
Sponsor Name:Sellas Life Sciences | |||||||||||||
Full Title: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid ... | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) HU (Completed) IT (Trial now transitioned) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000624-33 | Sponsor Protocol Number: HO156_AMLSG28/18 | Start Date*: 2019-08-01 | ||||||||||||||||
Sponsor Name:HOVON Foundation | ||||||||||||||||||
Full Title: A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with ne... | ||||||||||||||||||
Medical condition: Previously untreated Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) SE (Trial now transitioned) LT (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002864-36 | Sponsor Protocol Number: PKRPC001 | Start Date*: 2021-11-04 | |||||||||||
Sponsor Name:Priothera S.A.S. | |||||||||||||
Full Title: A prospective randomized, double-blind, placebo-controlled, multi-center phase IIb study to evaluate the efficacy and safety of mocravimod in acute myeloid leukemia (AML) patients undergoing alloge... | |||||||||||||
Medical condition: Patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
